[en] Brivaracetam is a synaptic vesicle protein 2A ligand in phase III development for epilepsy. A phase I, open-label, randomized study was conducted in 42 healthy male participants to assess the effect of brivaracetam on CYP3A activity using midazolam as a probe. Participants were randomized to oral brivaracetam 5, 50, or 150 mg/day from Day 8 to Day 14. A single oral dose (7.5 mg) of midazolam was administered on Days 1, 13, and 20, and full pharmacokinetic profiles were obtained. For all brivaracetam doses, the areas under the plasma concentration-time curves from 0 to infinity (AUCinf ) for midazolam and 1'-hydroxymidazolam were similar on Days 13 and 20 compared with Day 1. Following brivaracetam 150 mg/day, the Day 13/Day 1 AUCinf ratio (90% confidence interval) was 1.09 (0.97, 1.21) and 1.04 (0.93, 1.17) for midazolam and 1'-hydroxymidazolam, respectively. For the Day 20/Day 1 comparison, the corresponding AUCinf ratios were 1.10 (0.98, 1.23) and 1.07 (0.97, 1.18). Maximum midazolam plasma concentration was increased on both Day 13 and Day 20 vs. Day 1 but the relevance of this finding was unclear. This study indicates that brivaracetam up to 150 mg/day has no significant inducing or inhibiting effect on CYP3A activity.
Disciplines :
Pharmacie, pharmacologie & toxicologie
Auteur, co-auteur :
Stockis, Armel
Watanabe, Shikiko
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques
Langue du document :
Anglais
Titre :
Effect of brivaracetam on CYP3A activity, measured by oral midazolam.
Date de publication/diffusion :
2015
Titre du périodique :
Journal of Clinical Pharmacology
ISSN :
0091-2700
eISSN :
1552-4604
Maison d'édition :
Wiley, Hoboken, Etats-Unis - New Jersey
Peer reviewed :
Peer reviewed vérifié par ORBi
Commentaire :
(c) 2015, The American College of Clinical Pharmacology.
Kenda BM, Matagne AC, Talaga PE, et al. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem. 2004; 47 (3): 530-549.
Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res. 2013; 103 (1): 2-30.
Biton V, Berkovic SF, Abou-Khalil B, et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014; 55: 57-66.
Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S,. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014; 55: 47-56.
Sargentini-Maier ML, Rolan P, Connell J, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol. 2007; 63 (6): 680-688.
Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A,. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy males. Br J Clin Pharmacol. 2008; 66 (1): 71-75.
Sargentini-Maier ML, Espie P, Coquette A, Stockis A,. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008; 36 (1): 36-45.
Stockis A, Watanabe S, Rouits E, Matsuguma K, Irie S,. Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: Influence of CYP2C19 genotype. Drug Metab Pharmacokinet. 2014; 29 (5): 394-399.
Nicolas JM, Chanteux H, Rosa M, Watanabe S, Stockis A,. Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos. 2012; 40 (8): 1466-1472.
Scheen AJ,. Cytochrome P450-mediated cardiovascular drug interactions. Expert Opin Drug Metab Toxicol. 2011; 7 (9): 1065-1082.
Stockis A, Rolan P,. Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women. J Clin Pharmacol. 2013; 53 (12): 1313-1321.
Schmiedlin-Ren P, Thummel KE, Fisher JM, et al. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol Pharmacol. 1997; 51 (5): 741-754.
French JA, Costantini C, Brodsky A, von Rosenstiel P,. Adjunctive brivaracetam for refractory partial-onset seizures. A randomized, controlled trial. Neurology. 2010; 75 (6): 519-525.
van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P,. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013; 54 (1): 89-97.
Greenblatt DJ,. Drug interaction studies with CYP3A substrates: how much inhibitor pre-exposure is needed. Clin Pharmacol Drug Dev. 2012; 1 (3): 83-84.
Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandstrom R,. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther. 2008; 84 (1): 52-62.
Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ,. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998; 54 (1): 53-58.
Huang SM, Temple R, Throckmorton DC, Lesko LJ,. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther. 2007; 81 (2): 298-304.
Chen M, Nafziger AN, Bertino JS. Jr,. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. Drug Metab Dispos. 2006; 34 (12): 2079-2082.
Mueller SC, Drewelow B,. Evaluation of limited sampling models for prediction of oral midazolam AUC for CYP3A phenotyping and drug interaction studies. Eur J Clin Pharmacol. 2013; 69 (5): 1127-1134.
Halama B, Hohmann N, Burhenne J, et al. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther. 2013; 93 (6): 564-571.
